Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-08-17 5:30 pm Sale | 2026-08-13 | 13D | BRIDGEBIO PHARMA INC BBIO | KKR Genetic Disorder L.P. | 9,232,739 4.700% | -4,028,232 (-30.38%) | Filing History |
| 2026-08-03 08:31 am Purchase | 2026-06-30 | 13G | BRIDGEBIO PHARMA INC BBIO | Farallon Capital Management, L.L.C. | 10,743,063 5.500% | 10,743,063 (New Position) | Filing History |
| 2026-07-27 4:25 pm Sale | 2026-06-30 | 13G | BRIDGEBIO PHARMA INC BBIO | BlackRock, Inc. BLK | 9,733,762 4.960% | -3,145,077 (-24.42%) | Filing History |
| 2026-07-10 7:03 pm Sale | 2026-07-09 | 13D | BRIDGEBIO PHARMA INC BBIO | VIKING GLOBAL INVESTORS LP | 9,792,219 5.000% | -2,050,215 (-17.31%) | Filing History |
| 2026-05-29 4:48 pm Purchase | 2026-05-22 | 13G | BRIDGEBIO PHARMA INC BBIO | Farallon Capital Partners, L.P. | 10,226,063 5.200% | 10,226,063 (New Position) | Filing History |
| 2026-05-15 12:36 pm Purchase | 2026-03-31 | 13G | BRIDGEBIO PHARMA INC BBIO | JANUS HENDERSON GROUP Ltd. JHG | 13,179,013 6.800% | 2,178,556 (+19.80%) | Filing History |
| 2026-04-16 4:35 pm Sale | 2026-03-31 | 13G | BRIDGEBIO PHARMA INC BBIO | Kumar Neil | 9,282,982 4.600% | -1,183,730 (-11.31%) | Filing History |
| 2026-04-02 6:40 pm Sale | 2026-03-31 | 13D | BRIDGEBIO PHARMA INC BBIO | VIKING GLOBAL INVESTORS LP | 11,842,434 6.100% | -1,183,933 (-9.09%) | Filing History |
| 2026-03-26 4:41 pm Sale | 2026-03-13 | 13G | BRIDGEBIO PHARMA INC BBIO | The Vanguard Group | 0 0.000% | -16,484,985 (Position Closed) | Filing History |
| 2026-02-17 8:46 pm Sale | 2026-02-12 | 13D | BRIDGEBIO PHARMA INC BBIO | VIKING GLOBAL INVESTORS LP | 13,026,367 6.800% | -2,867,567 (-18.04%) | Filing History |
| 2026-02-17 12:43 pm Purchase | 2025-12-31 | 13G | BRIDGEBIO PHARMA INC BBIO | JANUS HENDERSON GROUP Ltd. JHG | 11,000,457 5.700% | 11,000,457 (New Position) | Filing History |
| 2025-11-14 4:52 pm Sale | 2025-11-14 | 13D | BRIDGEBIO PHARMA INC BBIO | VIKING GLOBAL INVESTORS LP | 15,893,934 8.200% | -2,708,986 (-14.56%) | Filing History |
| 2025-11-14 12:19 pm Purchase | 2025-09-30 | 13G | BRIDGEBIO ONCOLOGY THERAPEUTIC BBOT | T. Rowe Price Associates, Inc. | 885,042 1.100% | 885,042 (New Position) | Filing History |
| 2025-08-14 8:32 pm Unchanged | 2025-08-14 | 13D | BRIDGEBIO PHARMA INC BBIO | VIKING GLOBAL INVESTORS LP | 18,602,920 9.700% | 0 (Unchanged) | Filing History |
| 2025-07-29 11:20 am Purchase | 2025-06-30 | 13G | BRIDGEBIO PHARMA INC BBIO | The Vanguard Group | 16,484,985 8.680% | 3,684,691 (+28.79%) | Filing History |
| 2025-07-01 7:49 pm Sale | 2025-06-27 | 13D | BRIDGEBIO PHARMA INC BBIO | VIKING GLOBAL INVESTORS LP | 18,602,920 9.800% | -3,452,455 (-15.65%) | Filing History |
| 2025-05-14 5:52 pm Sale | 2025-05-12 | 13D | BRIDGEBIO PHARMA INC BBIO | KKR Genetic Disorder L.P. | 13,260,971 7.000% | -6,000,000 (-31.15%) | Filing History |
| 2025-03-12 4:28 pm Unchanged | 2025-01-31 | 13D | BRIDGEBIO PHARMA INC BBIO | VIKING GLOBAL INVESTORS LP | 22,055,375 11.700% | 0 (Unchanged) | Filing History |
| 2025-03-07 6:15 pm Sale | 2025-03-05 | 13D | BRIDGEBIO PHARMA INC BBIO | KKR Genetic Disorder L.P. | 19,260,971 10.100% | -6,000,000 (-23.75%) | Filing History |
| 2025-02-13 5:23 pm Purchase | 2024-12-31 | 13G | BRIDGEBIO PHARMA INC BBIO | Kumar Neil | 10,466,712 5.410% | 507,208 (+5.09%) | Filing History |